SLC5A2 and diabetes mellitus: SGLT2 is improve HF and CKD outcomes, regardless of diabetes status - GLP-1RAs support weight loss and improve ASCVD and liver disease outcomes - Tirzepatide shows superior results in weight reduction (>20%), diabetes prevention, and MASLD improvement